Exciting Approval in Europe for HER2-Positive Breast Cancer
EP. 1: European Commission Approval of Tucatinib in HER2+ BC
Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf
Volkmar Mueller, MD, reviews recent data from the HER2CLIMB trial and discusses the recent regulatory approval in Europe for patients with HER2+ breast cancer.
EP. 2: Favorable Safety Profile of Tucatinib for Metastatic HER2+ BC
Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf
Experts in breast oncology review the favorable safety profile of tucatinib for patients with metastatic HER2+ breast cancer.
EP. 3: Real-World Experience With Tucatinib in Germany and France
Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf
An examination of the real-world data supporting the use of tucatinib for patients with metastatic HER2+ breast cancer in Europe.
EP. 4: Clinical Implications of Tucatinib Approval in Europe
Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf
Experts discuss the clinical implications of the approval of tucatinib in Europe, specifically for patients with active brain metastases.
EP. 5: Approaches to Sequencing for Metastatic HER2+ BC
Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf
Volkmar Mueller, MD, shares insight on the potential sequencing of available therapeutics for patients with metastatic HER2+ breast cancer.
